TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01461915

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab paclitaxel
Description: Nab-paclitaxel 125 mg/m2 will be administered IV over 30 minutes. Nab-paclitaxel will be administered weekly for 3 weeks followed by 1 week of rest (28-day cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Nab-paclitaxel 125 mg/m2 will be administered IV over 30 minutes. Nab-paclitaxel will be administered weekly for 3 weeks followed by 1 week of rest (28-day cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Following the completion of nab-paclitaxel administration, gemcitabine IV infusion at 1000 mg/m2 will be administered over 30 minutes. Gemcitabine will be administered weekly for 3 weeks followed by 1 week of rest (28-cycle).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Following the completion of nab-paclitaxel administration, gemcitabine IV infusion at 1000 mg/m2 will be administered over 30 minutes. Gemcitabine will be administered weekly for 3 weeks followed by 1 week of rest (28-cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Following the completion of nab-paclitaxel administration, gemcitabine IV infusion at 1000 mg/m2 will be administered over 30 minutes. Gemcitabine will be administered weekly for 3 weeks followed by 1 week of rest (28-cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dociparstat
Description: Following the completion of gemcitabine administration, dociparstat IV bolus at 4 mg/kg will be administered in 5 minutes immediately after completion of gemcitabine administration. Immediately following the dociparstat IV bolus administration, dociparstat 48-hour IV continuous infusion at 0.375 mg/kg/hr will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dociparstat
Description: Following the completion of gemcitabine administration, dociparstat IV bolus at 4 mg/kg will be administered in 5 minutes immediately after completion of gemcitabine administration. Immediately following the dociparstat IV bolus administration, dociparstat 48-hour IV continuous infusion at 0.375 mg/kg/hr will be administered.
Study: NCT04575311

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AB680
Description: AB680 is a Cluster of Differentiation (CD)73 Inhibitor

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study: NCT01984827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: 1. a single oral dose of 400mg Moxifloxacin plus a hyper-glycaemic clamp for 4 hours~2. a single oral dose of 400mg Moxifloxacin plus C-peptide~3. a single oral dose of 400mg Moxifloxacin~4. placebo~Oral doses of placebo and moxifloxacin will be administered by a Research Physician or Pharmacy staff member between 08:00 a.m. and 10:00 a.m.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin
Description: 1. a single oral dose of 400mg Moxifloxacin plus a hyper-glycaemic clamp for 4 hours~2. a single oral dose of 400mg Moxifloxacin plus C-peptide~3. a single oral dose of 400mg Moxifloxacin~4. placebo~Oral doses of placebo and moxifloxacin will be administered by a Research Physician or Pharmacy staff member between 08:00 a.m. and 10:00 a.m.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hyper-glycaemic clamp
Description: a hyper-glycaemic clamp only for 2 hours followed by a hyper-glycaemic clamp plus C-peptide for 2 hours
Study: NCT04907617

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination
Description: After the induction of anaesthesia, for patients assigned to groups 3, the cover of the forced-air warming device (Bair HuggerTM Warming Unit, Model 505, Augustine Medical Inc., Eden Prairie, MN, USA) will be covered over the patient, with the surgical site exposed, and the temperature adjustment of the device will be set to the maximum (43°C). Then, the temperature will be adjusted to maintain a patient temperature of at least 36.5°C. When the patient's body temperature reaches 37°C, the device will be turned off and it will be restarted at a temperature measurement of \<36.5°C.~In patients assigned to groups 3, intraoperative IV (Automer blood/fluid warming system, Acemedikal, South Korea) and irrigation fluids (Enthermic Warming Cabinet 1002W, Poland) will be given by heating to 37°C in a thermostatically controlled heating cabinet.
Study: NCT02446756

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Study: NCT04907617

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: The patients assigned to group 4 will only receive 'routine care'. They will not be given intraoperative forced-air warming or heated IV and irrigation fluids.
Study: NCT02446756

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physiotherapy
Study: NCT01171261

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Games Field Trial
Description: There were 4 arms to the intervention in the field trial of this study. Participants were randomized to one of 4 arms or exergame that were manufactured by SSD/Xavix (Shiseido Co. of Japan). Each exergame consisted of a game cartridge, the XavixPort, and game controllers (e.g., tennis racquets, boxing gloves, bowling ball, or floor mat). The XavixPort interfaces the exergame with the participant's television and contains the infrared sensors that track the movement of the game controllers. Each exergame cartridge includes multiple game modes. The four arms/exergames were: XaviX Tennis, The Jackie Chan Studio Fitness (J-MAT), XaviX Bowling, and XaviX Boxing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Games Field Trial
Description: There were 4 arms to the intervention in the field trial of this study. Participants were randomized to one of 4 arms or exergame that were manufactured by SSD/Xavix (Shiseido Co. of Japan). Each exergame consisted of a game cartridge, the XavixPort, and game controllers (e.g., tennis racquets, boxing gloves, bowling ball, or floor mat). The XavixPort interfaces the exergame with the participant's television and contains the infrared sensors that track the movement of the game controllers. Each exergame cartridge includes multiple game modes. The four arms/exergames were: XaviX Tennis, The Jackie Chan Studio Fitness (J-MAT), XaviX Bowling, and XaviX Boxing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Games Field Trial
Description: There were 4 arms to the intervention in the field trial of this study. Participants were randomized to one of 4 arms or exergame that were manufactured by SSD/Xavix (Shiseido Co. of Japan). Each exergame consisted of a game cartridge, the XavixPort, and game controllers (e.g., tennis racquets, boxing gloves, bowling ball, or floor mat). The XavixPort interfaces the exergame with the participant's television and contains the infrared sensors that track the movement of the game controllers. Each exergame cartridge includes multiple game modes. The four arms/exergames were: XaviX Tennis, The Jackie Chan Studio Fitness (J-MAT), XaviX Bowling, and XaviX Boxing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Games Field Trial
Description: There were 4 arms to the intervention in the field trial of this study. Participants were randomized to one of 4 arms or exergame that were manufactured by SSD/Xavix (Shiseido Co. of Japan). Each exergame consisted of a game cartridge, the XavixPort, and game controllers (e.g., tennis racquets, boxing gloves, bowling ball, or floor mat). The XavixPort interfaces the exergame with the participant's television and contains the infrared sensors that track the movement of the game controllers. Each exergame cartridge includes multiple game modes. The four arms/exergames were: XaviX Tennis, The Jackie Chan Studio Fitness (J-MAT), XaviX Bowling, and XaviX Boxing.
Study: NCT02012049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperdal OD Tab. 2mg
Description: 1 tablet Risperdal OD 2 mg administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperdal OD Tab. 2mg
Description: 1 tablet Risperdal OD 2 mg administered orally.
Study: NCT02386124

Intervention type: OTHER
Group type: OTHER
Intervention: frailty evaluation
Description: assessment of mental and physical frailty before discharge from cardiac departement
Study: NCT02012049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperdal Quicklet Tab. 2mg
Description: 1 tablet Risperdal Quicklet Tab. 2mg administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperdal Quicklet Tab. 2mg
Description: 1 tablet Risperdal Quicklet Tab. 2mg administered orally.
Study: NCT01940627

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ubiquinol
Description: Ubiquinol 200mg/day (two capsules of 100 mg (Breakfast and lunch)) for 14 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: placebo capsules (two capsules (Breakfast and lunch)) for 14 days
Study: NCT03787992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alflutinib Mesylate (AST2818) 80mg//40 mg+ placebo
Description: The initial dose of AST2818 80 mg once daily can be reduced to 40 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Gefitinib 250 mg
Description: The initial dose of Placebo Gefitinib 250 mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefitinib 250 mg
Description: The initial dose of Gefitinib 250mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo AST2818 80mg//40 mg
Description: The initial dose of Placebo AST2818 80 mg once daily can be reduced to Placebo AST2818 40 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
Study: NCT02750956

Intervention type: PROCEDURE
Intervention: Non-surgical periodontal treatment
Description: Non-surgical periodontal therapy is an anti-infective therapy which includes both mechanical and chemotherapeutic approaches to minimize or eliminate microbial biofilm, the primary etiology of gingivitis and periodontitis

Intervention type: PROCEDURE
Intervention: Non-surgical periodontal treatment
Description: Non-surgical periodontal therapy is an anti-infective therapy which includes both mechanical and chemotherapeutic approaches to minimize or eliminate microbial biofilm, the primary etiology of gingivitis and periodontitis
Study: NCT01229137

Intervention type: DEVICE
Intervention: SRD-1 conversion
Study: NCT01116973

Intervention type: OTHER
Group type: OTHER
Intervention: PICC
Description: Peripheral inserted catheter placement to take the reading

Intervention type: OTHER
Group type: OTHER
Intervention: PICC
Description: Peripheral inserted catheter placement to take the reading
Study: NCT01612208

Intervention type: DEVICE
Intervention: Periarticular Locking Plate (NCB, Zimmer)
Description: The proximal plate segment will be applied to the diaphysis using four 5.0 mm MotionLoc screws. The plate will not be compressed onto the femoral diaphysis to preserve periosteal perfusion and to enable controlled motion between the plate and the diaphysis. If desirable, temporary spacers of the NCB set may be used in the proximal plate segment to facilitate 1-2 mm plate elevation over the diaphysis. Only MotionLoc screws will be used for fixation of the NCB plate proximal to the fracture site.

Intervention type: DEVICE
Intervention: MotionLoc Screw
Description: The NCB Polyaxial Locking Plate System is indicated for temporary internal fixation and stabilization of fractures and osteotomies of long bones. These MotionLoc screws have a reduced 3.4 mm diameter mid-shaft section to bypass the near cortex. By avoiding rigid constraint in the near cortex, the MotionLoc screw design increases the working length of the screw, allowing for elastic flexion of the screw shaft within a controlled motion envelope in the near cortex.
Study: NCT03322033

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Valiant PS-IDE Stent Graft
Description: Medtronic Valiant PS-IDE Stent Graft System with the Captivia Delivery System
Study: NCT01498458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib plus capecitabine
Description: Patients will receive pazopanib tablets once daily at a dose according to the allocated dose level:~* dose level I: 400 mg~* dose level II: 600 mg~* dose level III: 800 mg~In addition patients receive capecitabine at the same oral dose for all dose levels with 1600 mg/m2 on days 1 to 14 every 3 weeks.~Treatment will be given until disease progression or unacceptable toxicity of the study drug, or withdrawal of consent of the patient.~Six patients will be recruited in each dose level. If less than 2 out of 6 patients experience a DLT within the first 2 cycles (weeks 1 to 6), the next dose level is started. Once the MTD is established, additional 6 patients will be included into this dose level to further characterise the safety of the dose regimen.~If it is reported, that two patients had a DLT, all patients are informed about it and the dose level immediately reduced by one dose level.
Study: NCT02314975

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcceleDent vibrational device
Description: Supplementary vibrational force with fixed appliances
Study: NCT00783081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-134
Description: K-134 is given as low dose mid dose and high dose tablets for 26 Weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-134
Description: K-134 is given as low dose mid dose and high dose tablets for 26 Weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-134
Description: K-134 is given as low dose mid dose and high dose tablets for 26 Weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol 100 mg BID
Description: Cilostazol 100mg BID for 26 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo BID for 26 weeks.
Study: NCT00758589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1981
Description: Oral tablet, 50 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1981
Description: Oral tablet, 400 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1981
Description: Oral tablet, 1000 mg twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00290667

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: pegfilgrastim

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: pegfilgrastim

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rituximab

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rituximab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine sulfate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine sulfate
Study: NCT01229137

Intervention type: DEVICE
Intervention: SRD-1 conversion

Intervention type: DEVICE
Intervention: SRD-1 conversion
Study: NCT00290667

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pharmacological study
Study: NCT03295630

Intervention type: DEVICE
Group type: OTHER
Intervention: Accelerometer
Description: Participants will perform a semi-structured movement protocol to investigate the ability of the Actigraph GT3X accelerometer to identify body position (lying, sitting or standing) and quantify step count.
Study: NCT04509934

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Connective Tissue Manipulation
Description: The position of the patients during treatment sessions was sitting with the hips and knees at 90° flexion and feet supported, arms relaxed on the thighs, back naked and straight, allowing optimal tension of the connective tissue. The CTM procedure consisted of treating 3 sections in the back. These sections were basic (sacral and lumbar regions), lower thoracic (L1 through T7) and anterior pelvic. All sessions were ended with bilateral long strokes to the iliac crest and subcostal regions. The physiotherapist applied strokes bilaterally by her middle finger of the right or left hand to the defined zones of the mentioned sections in the back. The treatment started from the basic section, and progress to other regions was decided according to the vascular reaction of the connective tissue. Each session lasted for 5 to 20 minutes, depending on the extent of the treated area.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Connective Tissue Manipulation
Description: The position of the patients during treatment sessions was sitting with the hips and knees at 90° flexion and feet supported, arms relaxed on the thighs, back naked and straight, allowing optimal tension of the connective tissue. The CTM procedure consisted of treating 3 sections in the back. These sections were basic (sacral and lumbar regions), lower thoracic (L1 through T7) and anterior pelvic. All sessions were ended with bilateral long strokes to the iliac crest and subcostal regions. The physiotherapist applied strokes bilaterally by her middle finger of the right or left hand to the defined zones of the mentioned sections in the back. The treatment started from the basic section, and progress to other regions was decided according to the vascular reaction of the connective tissue. Each session lasted for 5 to 20 minutes, depending on the extent of the treated area.
Study: NCT02751671

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: POCUS
Description: The use of Point-of-care ultrasound before urine sample procedure
Study: NCT00290667

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pharmacological study

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Study: NCT02751671

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard
Description: Urine sampling procedure without prior ultrasound
Study: NCT03200717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Participants received 800mg of pazopanib once daily orally. Pazopanib was supplied as aqueous film-coated tablets containing 200 mg or 400 mg.
Study: NCT00290667

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Study: NCT04645745

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: myo-inositol, alpha-lactalbumin, folic acid
Description: Evaluating the improvement vs the baseline after three and six months of treatment
Study: NCT04631965

Intervention type: BEHAVIORAL
Intervention: Transition support service
Description: The hospital-wide transition support service provides systematic care coordination for young patients prior to the transfer of care
Study: NCT02314975

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham AcceleDent device
Description: Supplementary sham-vibrational device with fixed appliances

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fixed appliance only
Description: Fixed appliance treatment only
Study: NCT03382704

Intervention type: DIAGNOSTIC_TEST
Intervention: Examination for presence or absence of lanugo hairs
Description: Pre-operative examination for presence or absence of lanugo hairs
Study: NCT02648555

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily walking
Description: Participants will be instructed to walk briskly for \>40 minutes, 7 days a week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary recommendations
Description: Participants will be instructed to eat at least two daily servings of meat, poultry, fish (e.g. 2 g/kg) or other protein-rich food, starting at least one week before embryo transfer and continuing until delivery. They will be also recommended to avoid high-glycemic index meals (high-carbohydrate, low-fiber), such as snacks, candies, fiber-free juices, coconut water, and sugar-sweetened beverages, particularly carbonated soft drinks and sport drinks.~Patients suffering from nausea usually do not tolerate solid food. As a result, fiber-free juices and sugar-sweetened beverages account of most of their caloric intake, which may cause non-adherence to the protocol. Women with nausea or vomiting will be treated with ondansetron.
Study: NCT00594282

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiolucent cushion
Description: MammoPad radiolucent breast plate cushion used during mammogram
Study: NCT02099188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 80 mg/m2 or 33 mg/m2/day or 100 mg/m2 - Concentrate for solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2 - Concentrate for solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 800 mg/m2/day - Concentrate for solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 150 mg/m2/day - Concentrate for solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin
Description: 20 mg/m2/day - Powder for solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: 3000 mg/m2/day - Powder for solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 250 mg/m2/day - Powder for solution for infusion
Study: NCT01028131

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Participants randomized by the computer into this condition will view a 20-minute music and tv videos after completing the brief assessment. The research assistant will then briefly describe the CM process, with a period for questions to assure understanding. The CM condition will involve participant-initiated submission of urine samples at prenatal visits. Clinic staff will have no responsibility for the CM component other than calling research staff when a participant wishes to submit a sample. Clinic staff will not schedule any new, additional, or unnecessary prenatal visits.